SEP 2·SEC EDGARLow
Kitayama Mitchell W sold (to issuer) $315K of ASTH
Kitayama Mitchell W sold (to issuer) 8,500 shares of Astrana Health, Inc. (ASTH) at $37.09 ($0.32M total) on 2026-08-31.
StockNASDAQ · US · USDHealthcare · Medical Care Facilities
$ASTH
Astrana Health, Inc.
Price · $ASTHvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ASTH in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $315K 1 txs
Kitayama Mitchell W1× · $315K
10b5-1 share of filings0%
Top stories · $ASTHMore →
AUG 27·yahoo.com
Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks
Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.
AUG 18·SEC EDGAR
Schmidt David sold (to issuer) $772K of ASTH
Schmidt David sold (to issuer) 20,000 shares of Astrana Health, Inc. (ASTH) at $38.59 ($0.77M total) on 2026-08-14.
ASTH sentiment & insider activity
Recent ASTH coverage spans earnings, insider activity and financial news.
In the last 30 days, ASTH insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($315K). The most active reporter was Kitayama Mitchell W with 1 filing.
What's driving ASTH
The insider sale modestly reduces insider ownership, potentially signaling limited confidence.
Mixed results may pressure the stock despite revenue growth.
This is an insider sale to the issuer (buyback participation style), which can be mildly negative for sentiment but is not a fundamental change by itself.
Guidance raise plus leverage improvement and FCF conversion support a constructive near-term earnings outlook, but Medicaid attrition and CMS billing adjustments remain key swing factors.
Raised guidance with mixed quality signals: broad outperformance and manageable costs, but wide Q4 EBITDA range and Medicaid attrition remain key risks.
AlphAI scores every news story that mentions ASTH with an AI model for sentiment and relevance, and aggregates insider trades from Astrana Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ASTH
Score
Kitayama Mitchell W sold (to issuer) $315K of ASTH
Kitayama Mitchell W sold (to issuer) 8,500 shares of Astrana Health, Inc. (ASTH) at $37.09 ($0.32M total) on 2026-08-31.
1 min read
Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks
Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.
3 min readSchmidt David sold (to issuer) $772K of ASTH
Schmidt David sold (to issuer) 20,000 shares of Astrana Health, Inc. (ASTH) at $38.59 ($0.77M total) on 2026-08-14.
1 min read
Astrana Health (ASTH) Q2 2026 Earnings Call Transcript
Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.
7 min read
Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised
Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.
4 min read
Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non
Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.
6 min readAstrana Health, Inc. (ASTH): Results of Operations and Financial Condition
Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET · Reports revenue of $972.5 million, up 49% year-over-year, net income of $18.5 million, up 81% year-over-year, and adju
6 min read
Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call
Astrana Health, Inc. (NASDAQ: ASTH) said it will release second-quarter 2026 financial results for the period ended June 30, 2026 after the market close on Aug. 6, 2026. The company will host a conference call that day at 2:30 p.m. PT/5:30 p.m. ET, with a webcast and slide deck on its IR calendar.
2 min read
Astrana Health Strengthens Leadership Team to Accelerate Long-Term Growth
Astrana Health (NASDAQ: ASTH) appointed Daniel Rothman as President of Physician Enterprise and Vishal Gupta as Senior Vice President of Enterprise Transformation to strengthen its executive leadership team. The company said the roles will support scaling its physician network and enterprise finance, operations, and reporting capabilities for long-term growth.
3 min readAstrana Health, Inc. (ASTH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001083446 0001083446 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report
3 min read